Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 7.59%
As of Tuesday, October 20, Jade Biosciences, Inc.’s JBIO share price has surged by 7.59%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Commentary & Analysis
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.80%
As of Wednesday, September 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.80%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 10.02%
As of Wednesday, September 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 10.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 5.14%
As of Thursday, September 17, Jade Biosciences, Inc.’s JBIO share price has surged by 5.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.68%
As of Thursday, September 03, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $937.4 | $227.8 | 45% |
|
| Shares Out (Mil) | 61.1 | 53.4 | 52% |
|
| Institutional Ownership | 99.7% | 92.9% | 92% |
|
| Float (Mil) | 52.0 | 41.2 | 47% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 818 | 513 | 67% |
|
| Price Change (52-week) |
47.4% | 47.3% | 85% |
|
| Growth | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.786) | ($2.932) | ($2.663) | |
| Month Ago EPS | ($0.786) | ($2.932) | ($2.663) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.565) | ($2.282) | ($2.280) | |
| Year/Year Chg | 3.8% | (8.2%) | (26.7%) | |
| Financials | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($153) | ($44) | 8% |
|
| EPS (TTM) | ($2.343) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($124) | ($34) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($114) | $2 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $605 | $177 | 36% |
|
| Valuation | JBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.13 | 2.22 | 56% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (44.0%) | (47.1%) | 13% |
|
| ROE | (47.8%) | (53.3%) | 16% |
|
| Liabilities to Assets | 6.8% | 29.3% | 4% |
|
| F-Score | 2 | 2 | na |
|
Jade Biosciences, Inc. did not pass any screens on 10/27/2026.
